Tritonix.ai

News / Korea / yonhap_finance

Alteogen Shares Fall Despite 4.4 Trillion KRW Novartis Deal

Health Technology · Biotechnology · yonhap_finance · 2026-09-03

196170

Alteogen shares dropped over 5% on profit-taking despite announcing a major licensing agreement with Novartis worth up to 4.4 trillion KRW.

What Happened

Major Licensing Deal: Alteogen has signed a licensing and option agreement with Novartis to develop and commercialize subcutaneous formulations using its ALT-B4 technology. The deal could potentially bring the company up to 4.41 trillion KRW upon reaching development and commercial milestones.

Stock Price Volatility: Despite the positive news, Alteogen's stock price experienced a sharp reversal after an initial morning rally. The stock eventually closed at 283,000 KRW, down 5.19% from the previous trading session.

Technological Foundation: The core of the agreement, ALT-B4, is a recombinant human hyaluronidase developed using Alteogen's proprietary Hybrozyme platform. This technology enables the conversion of intravenous drugs into subcutaneous injections, significantly improving patient convenience.

Market Analysis: Analysts attribute the decline to profit-taking following the announcement of the massive deal. The stock's failure to maintain its intraday high of 313,500 KRW suggests that investors were looking to lock in gains after the recent rally.

Read original

More in Health Technology

Taiho Oncology's Anti-Thrombotic Film Enters FDA Review, Targeting 2026 Launch

Health Technology · economic_daily · 2026-09-06

Taiho Oncology's BEQIA anti-thrombotic film has entered standard FDA review, with a target completion date of April 22 next year.

6467

Adimmune August Revenue Grows 34% YoY

Health Technology · cnyes · 2026-09-04

Adimmune (4142) reported August revenue of NT$97.92 million, a 34.46% year-over-year increase, showing resilience compared to the biotech sector index.

4142

Huaan Plans $300 Million Capital Raise to Accelerate Drug Trials and Licensing

Health Technology · cnyes · 2026-09-04

Taiwan-based Huaan (6657) is set to raise NT$300 million through a new share issuance to fund clinical trials for its F705PD and F703EB drug candidates.

6657

Latest in Korea

U.S. Financial System Faces 'Backdoor' as Billions in Iranian Funds Bypass Sanctions

Finance · yonhap_finance · 2026-09-06

Despite strict U.S. sanctions, billions of dollars in Iranian funds are flowing through American banks annually by leveraging shell companies and foreign intermediaries.

FSS Tightens Rules on Target-Date Funds and Bank Loan Notifications

Finance · yonhap_finance · 2026-09-06

South Korea's financial regulator is strengthening disclosure requirements for target-date funds and mandating prior notice for bank loan suspensions.

New System to Instantly Block Deceased Individuals' Financial Transactions

Finance · yonhap_finance · 2026-09-06

Starting September 11, South Korea will launch a system that automatically blocks all financial transactions under a deceased person's name.

FSS Launches 'Voice Phishing Prevention Week' Across Financial Sector

Finance · yonhap_finance · 2026-09-06

The Financial Supervisory Service is partnering with major financial associations to host a week-long campaign focused on preventing voice phishing scams.